Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Kusano, Hironori ^a   Akiba, Jun ^a   Ogasawara, Sachiko ^a   Sanada, Sakiko ^a   Yasumoto, Makiko ^a   Nakayama, Masamichi ^a   Ueda, Keiko ^a   Ueda, Kosuke ^a   Kurita, Takashi ^a   Todoroki, Keita ^a   Umeno, Yumi ^a   Nakashima, Osamu ^b   Yano, Hirohisa ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; PEGINTERFERON ALPHA2A; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; TUMOR VOLUME; ANIMAL; DRUG EFFECTS; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MICE; MICE, NUDE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84892575481     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083195     Document Type: Article

References (33)

1. Pestka S, Langer JA, Zoon KC, Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56: 727-777. doi:10.1146/annurev.bi.56.070187.003455. PubMed: 2441659.
2. Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55. doi:10.1634/theoncologist.6-1-34. PubMed: 11161227.
3. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT et al. (1993) Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 17: 389-394. doi:10.1002/hep.1840170307. PubMed: 8383088.
4. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H et al. (2005) Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 48: 64-70. doi:10.1159/000082097. PubMed: 15785092.
5. Miyake Y, Kobashi H, Yamamoto K (2009) Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 44: 470-475. doi:10.1007/s00535- 009-0024-z. PubMed: 19308310.
6. Miyake Y, Iwasaki Y, Yamamoto K (2010) Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer 127: 989-996. PubMed: 19957327.
7. Qu LS, Jin F, Huang XW, Shen XZ (2010) Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol 102: 796-801. doi:10.1002/jso.21741. PubMed: 20886584.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965. doi:10.1016/S0140-6736(01)06102-5. PubMed: 11583749.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982. doi:10.1056/NEJMoa020047. PubMed: 12324553.
10. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S et al. (2006) Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 26: 964-975. doi:10.1111/j.1478-3231.2006.01321.x. PubMed: 16953837.
11. Utsunomiya I, Iemura A, Yano H, Akiba J, Kojiro M (1999) Establishment and characterization of a new human hepatocellular carcinoma cell line, HAK-3, and its response to growth factors. Int J Oncol 15: 669-675. PubMed: 10493947.
12. Murakami T (1984) Establishment and characterization of human hepatoma cell line (KIM-1). Acta Hepatol Jpn 25: 532-539. doi:10.2957/kanzo.25.532.
13. Murakami T, Maruiwa M, Fukuda K, Kojiro M, Tanaka M, et al. (1988) Characterization of a new human hepatoma cell line (KYN-3) derived from the ascites of the hepatoma patient [Abstract]. Jpn J Cancer Res 292 Proceedings of the Japanese Cancer Association
14. Murakami T, Yano H, Maruiwa M, Sugihara S, Kojiro M (1987) Establishment and characterization of a human combined hepatocholangiocarcinoma cell line and its heterologous transplantation in nude mice. Hepatology 7: 551-556. doi:10.1002/hep.1840070322. PubMed: 3032760.
15. Haramaki M, Yano H, Iemura A, Momosaki S, Ogasawara S et al. (1997) A new human hepatocellular carcinoma cell line (HAK-2) forms various structures in collagen gel matrices. Hum Cell 10: 183-192. PubMed: 9436038.
16. Yano H, Iemura A, Fukuda K, Mizoguchi A, Haramaki M et al. (1993) Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Hepatology 18: 320-327. doi:10.1016/0270-9139(93)92802-7. PubMed: 8393423.
17. Yano H, Iemura A, Haramaki M, Momosaki S, Ogasawara S et al. (1996) A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions. J Hepatol 24: 413-422. doi:10.1016/S0168-8278(96) 80161-9. PubMed: 8738727.
18. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A et al. (1999) Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29: 1708-1717. doi:10.1002/hep. 510290624. PubMed: 10347112.
19. Yano H, Kojiro M, Nakashima T (1986) A new human hepatocellular carcinoma cell line (KYN-1) with a transformation to adenocarcinoma. In Vitro Cell Dev Biol 22: 637-646. doi:10.1007/BF02623477. PubMed: 2430933.
20. Yano H, Maruiwa M, Murakami T, Fukuda K, Ito Y et al. (1988) A new human pleomorphic hepatocellular carcinoma cell line, KYN-2. Acta Pathol Jpn 38: 953-966. PubMed: 2847482.
21. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N et al. (2004) Interferon-αCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 41: 782-789. doi:10.1016/j.jhep.2004.07.012. PubMed: 15519651.
22. Takemoto Y, Yano H, Momosaki S, Ogasawara S, Nishida N et al. (2004) Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo. Clin Cancer Res 10: 7418-7426. doi:10.1158/1078-0432.CCR-04-0279. PubMed: 15534119.
23. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ et al. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12: 195-202. doi:10.1021/bc000082g. PubMed: 11312680.
24. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO Classification of Tumours of the Digestive System (4th Revised edition). Lyon, France, IARC Press. pp. 225-227.
25. Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S et al. (2007) Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 110: 2493-2501. doi:10.1002/cncr.23033. PubMed: 17941012.
26. Gillespie G, Carter WA (1981-1982) Species specificity of interferon. Tex Rep Biol Med 41: 37-42. PubMed: 6184826.
27. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893. doi:10.1093/jnci/94.12.883. PubMed: 12072542.
28. Kojiro S, Yano H, Ogasawara S, Momosaki S, Takemoto Y et al. (2006) Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. J Gastroenterol Hepatol 21: 129-137. doi:10.1111/j.1440-1746.2005.04154.x. PubMed: 16706824.
29. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY et al. (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferonalpha administration. Cancer Res 58: 808-814. PubMed: 9485039.
30. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2429-2441. doi:10.1056/NEJMoa0707615. PubMed: 19052125.
31. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY et al. (2011) Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140: 840-849. doi:10.1053/j.gastro.2010.11.050. PubMed: 21129375.
32. Bruix J, Poynard T, Colombo M, Schiff E, Burak K et al. (2011) Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 140: 1990-1999. doi:10.1053/j.gastro.2011.03.010. PubMed: 21419770.
33. Nishiguchi S, Tamori A, Kubo S (2005) Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 48: 71-75. doi:10.1159/000082098. PubMed: 15785093.